A kind of preparation method of tissue engineered cornea

Abstract

The invention belongs to the technical field of tissue engineering, and provides a method for preparing a tissue-engineered cornea, which uses a scaffold material prepared by combining human corneal limbal cells with animal-derived cornea, separates the anterior elastic layer, stroma layer, and posterior elastic layer, and coats Cloth the cell suspension prepared by human limbal cells, and then complete the construction of tissue engineered cornea containing cells by means of cross-linking and bonding. The tissue engineered cornea prepared by this method has high histocompatibility in use and can be industrialized advantages of preparation. At the same time, the cells used have not been expanded and cultured in vitro, and the properties of the cells are stable and difficult to differentiate, which ensures the safety of the tissue-engineered cornea.

Description

technical field [0001] The invention belongs to the technical field of tissue engineering, and in particular relates to a method for constructing a tissue engineering cornea. Background technique [0002] The cornea is one of the tissues that maintain the normal vision of the human body. Acute corneal injury, perforation, ulcers, lesions, etc. cause vision loss or blindness, or even enucleation, which has a great impact on the normal life and psychology of patients. [0003] Today, corneal blindness has become the second leading cause of blindness in the world. The most effective way to treat corneal blindness is corneal transplantation. However, the lack of corneal sources leads to lifelong blindness for patients who cannot be treated in time. According to statistics, about 4 million patients with corneal blindness in my country need corneal transplantation, but only less than 10,000 patients have donor corneas for transplantation. The scarcity of corneal donor sources res...

AI Technical Summary

Problems solved by technology

[0006] The current existing technology shows (such as Chinese patents 201410264542.X and 201410230365.3) that the artificial cornea prepared only provides scaffold materials and lacks seed cells with active functions. When it is implanted in the body for repair, it only relies on the repair ability of the patient's affected cells. Damage repair prolongs the treatment process, but also increases the probability of repair failure. At the same time, the scaffold material prepared by it is an exogenous material, which has poor compatibility with the patient's tissue after implantation, and there is a risk of rejection

[0007] Chinese patent 03140113.9 discloses an artificial tissue engineered biocornea, using epithelial and endothelial cells as seed cells, but the carrier used is animal tissue or allogeneic corneal components, which retains foreign aid cells or cell residual components, and does not The residual components are controlled and described, which will cause immune rejection and virus cross-infection in the human body, resulting in rejection of the implant by the patient after implantation and repair, resulting in treatment failure. At the same time, the seed cells used do not have differentiation pluripotency. The limitation of the therapeutic effect. At the same time, this kind of method needs to expand the cells by in vitro culture, which changes the living environment of the cells and increases the possibility of cell mutation. At the same time, the cell culture process is long, which delays the treatment process. , and may face a second operation, bringing potential harm to the patient's health

Images